American Century Companies Inc. Boosts Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

American Century Companies Inc. increased its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 80.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,014 shares of the company’s stock after purchasing an additional 47,704 shares during the period. American Century Companies Inc. owned 0.12% of Amylyx Pharmaceuticals worth $379,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC purchased a new position in Amylyx Pharmaceuticals in the 1st quarter worth approximately $35,000. Alpine Global Management LLC bought a new stake in Amylyx Pharmaceuticals in the 4th quarter worth approximately $45,000. R Squared Ltd increased its stake in Amylyx Pharmaceuticals by 99.9% in the 1st quarter. R Squared Ltd now owns 12,736 shares of the company’s stock worth $45,000 after acquiring an additional 6,366 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Amylyx Pharmaceuticals by 18.3% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company’s stock worth $61,000 after acquiring an additional 2,653 shares during the last quarter. Finally, Premier Path Wealth Partners LLC bought a new stake in Amylyx Pharmaceuticals in the 1st quarter worth approximately $72,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. The Goldman Sachs Group raised Amylyx Pharmaceuticals to a “buy” rating and set a $10.00 price objective on the stock in a research note on Thursday, July 10th. UBS Group raised Amylyx Pharmaceuticals to a “hold” rating in a research note on Tuesday, June 24th. Jefferies Financial Group assumed coverage on Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a “hold” rating on the stock. Mizuho lifted their price objective on Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 14th. Finally, Wall Street Zen raised Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Buy” and an average price target of $12.25.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX opened at $10.20 on Friday. The company has a market cap of $909.53 million, a P/E ratio of -4.08 and a beta of -0.44. The business’s 50 day moving average price is $8.15 and its 200-day moving average price is $5.71. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $2.28 and a fifty-two week high of $10.24.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.02). As a group, equities analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.